In an exclusive interview with The New Times, Nsanzimana said that there has been progress in setting up the facility since the arrival of the first BioNTainer -- facilities equipped to manufacture a range of mRNA-based vaccines -- in March and more have been coming in the country.
The manufacturing plant for mRNA-based vaccines with ISO-sized shipping containers is being built in the
"When you build something, you show the results and everyone is expecting the factory to be launched. That will happen before the end of this year to kick-off operations in research of vaccines and therapeutics, and vaccine manufacturing, though it will not be instant production as it's a process that takes time," Nsanzimana said.
At the ground breaking ceremony of the plant in
The development also includes the journey of
Nsanzimana noted that there is ongoing construction of a fully-fledged Rwanda FDA laboratory, which will be part of an ecosystem of factory production, regulatory systems and government will to create an environment for medical, pharmaceutical research and clinical trials.
Biopharmaceutical New Technologies (
Roughly, each BioNTainer consists of one drug substance and one formulation module for a total footprint of about 800 square metres.
The move to scale up vaccine production and enhance health systems resilience on the continent with such facility will be implemented in
Copyright 2023 The New Times. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com)., source